Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liting, Zhang, Haijun, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/
https://www.ncbi.nlm.nih.gov/pubmed/28261342
http://dx.doi.org/10.7150/jca.17144
_version_ 1782511615368757248
author Guo, Liting
Zhang, Haijun
Chen, Baoan
author_facet Guo, Liting
Zhang, Haijun
Chen, Baoan
author_sort Guo, Liting
collection PubMed
description Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.
format Online
Article
Text
id pubmed-5332892
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53328922017-03-03 Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor Guo, Liting Zhang, Haijun Chen, Baoan J Cancer Review Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients. Ivyspring International Publisher 2017-02-10 /pmc/articles/PMC5332892/ /pubmed/28261342 http://dx.doi.org/10.7150/jca.17144 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Guo, Liting
Zhang, Haijun
Chen, Baoan
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title_full Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title_fullStr Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title_full_unstemmed Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title_short Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
title_sort nivolumab as programmed death-1 (pd-1) inhibitor for targeted immunotherapy in tumor
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/
https://www.ncbi.nlm.nih.gov/pubmed/28261342
http://dx.doi.org/10.7150/jca.17144
work_keys_str_mv AT guoliting nivolumabasprogrammeddeath1pd1inhibitorfortargetedimmunotherapyintumor
AT zhanghaijun nivolumabasprogrammeddeath1pd1inhibitorfortargetedimmunotherapyintumor
AT chenbaoan nivolumabasprogrammeddeath1pd1inhibitorfortargetedimmunotherapyintumor

Ejemplares similares